RGMP 0.12 Regnum Corp.
| Range: | 1.0E-4-0.0059 | Vol Avg: | 0 | Last Div: | 0 | Changes: | -0.01 |
| Beta: | 2.62 | Cap: | 0.00B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Wed May 29 2019 | Empoloyees: | 1 | ||
| CUSIP: | 75915R106 | CIK: | 0001716324 | ISIN: | US75915R1068 | Country: | US |
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody CC chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company is based in New York, New York. Regnum Corp. is a subsidiary of Phoenixus AG.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow